Journal Information
Short Original
DOI: 10.1016/j.nefroe.2020.09.009
Open Access
Available online 20 August 2021
COVID-19 incidence and outcomes in a home dialysis unit in Madrid (Spain) at the height of the pandemic
Incidencia y resultados de la COVID-19 en una unidad de diálisis domiciliaria en Madrid (España) durante el pico de la pandemia
María Maldonadoa,
Corresponding author
, Marta Ossorioa,b, Gloria del Pesoa,b,c, Carlos Santos-Alonsoa, Laura Álvareza,b, Rafael Sánchez-Villanuevaa,b, Begoña Rivasa,b,d, Cristina Vegaa,b,d, Rafael Selgasa,b,c,d, María A. Bajoa,b,c,d
a Departamento de Nefrología, Hospital Universitario La Paz, Madrid, Spain
b Instituto de investigación La Paz (IdiPAZ), Madrid, Spain
c Red de Investigación Renal (REDINREN), Instituto de Salud Carlos III, Madrid, Spain
d Departamento de Nefrología, Universidad Autónoma de Madrid, Madrid, Spain
Received 15 August 2020. Accepted 27 September 2020
Article information
Full Text
Download PDF
Tables (4)
Table 1. Characteristics of home dialysis patients with and without COVID-19 infection.
Table 2. Clinical characteristics of COVID-19 infection.
Table 3. Comparison between survivors and non-survivors.
Table 4. Comparison between patients diagnosed with COVID-19 on home dialysis and in-centre HD from our hospital.
Show moreShow less

The 2019 coronavirus (COVID-19) is a viral infection caused by a new coronavirus that is affecting the entire world. There have been studies of patients on in-center hemodialysis (HD), but home dialysis population data are scarce. Our objective is to study the incidence and course of COVID-19 in a home dialysis unit (HDU) at the height of the pandemic.


an observational, retrospective study enrolling all patients diagnosed with COVID-19 from the HDU of Hospital Universitario La Paz [La Paz University Hospital] (Madrid, Spain) between March 10 and May 15, 2020. We collected clinical data from the HDU (57 patients on peritoneal dialysis [PD] and 22 patients on home hemodialysis [HHD]) and compared the clinical characteristics and course of patients with and without COVID-19 infection.


twelve patients were diagnosed with COVID-19 (9 PD; 3 HHD). There were no statistically significant differences in terms of clinical characteristics between patients with COVID-19 and the rest of the unit. The mean age was 62 ± 18.5 years; most were men (75%). All patients but one required hospitalization. Ten patients (83%) were discharged following a mean of 16.4 ± 9.7 days of hospitalization. Two patients were diagnosed while hospitalised for other conditions, and these were the only patients who died. Those who died were older than those who survived.


The incidence of COVID-19 in our HDU in Madrid at the height of the pandemic was high, especially in patients on PD. No potential benefit for preventing the infection in patients on home dialysis was observed. Advanced age and nosocomial transmission were the main factors linked to a worse prognosis.

Home dialysis
Home hemodialysis
Peritoneal dialysis

La enfermedad por coronavirus 2019 (COVID-19) es una infección viral causada por un nuevo coronavirus que está afectando a todo el mundo. Hay estudios previos de pacientes en hemodiálisis en centro (HD), pero hay pocos datos sobre población en diálisis domiciliaria. Nuestro objetivo es estudiar la incidencia y evolución de COVID-19 en una unidad de diálisis domiciliaria (UDD) durante el pico de la pandemia.


estudio observacional y retrospectivo que incluye todos los pacientes diagnosticados de COVID-19 de la UDD del Hospital Universitario La Paz (Madrid, España) entre el 10 de marzo y el 15 de mayo de 2020. Se recogieron los datos clínicos de la UDD (57 pacientes en diálisis peritoneal [PD] y 22 pacientes en hemodiálisis domiciliaria [HDD]) y comparamos las características clínicas y la evolución de los pacientes con o sin infección por COVID-19.


doce pacientes fueron diagnosticados de COVID-19 (9 DP, 3 HDD). No hubo diferencias estadísticamente significativas entre las características clínicas de los pacientes con COVID-19 y el resto de la unidad. La edad media fue 62 ± 18.5 años; la mayoría eran varones (75%). Todos los pacientes menos uno necesitaron hospitalización. Diez pacientes (83%) fueron dados de alta tras una media de 16,4 ± 9,7 días de hospitalización. Dos pacientes fueron diagnosticados durante su hospitalización por otro motivo y fueron los únicos que fallecieron. Los fallecidos eran de mayor edad que los supervivientes.


La incidencia de COVID-19 en nuestra UDD en Madrid durante el pico de la pandemia fue alto, especialmente en los pacientes en DP, sin observarse un potencial beneficio para prevenir la infección en los pacientes en diálisis domiciliaria. La edad avanzada y la transmisión nosocomial fueron los principales factores relacionados con peor pronóstico.

Palabras clave:
Diálisis domiciliaria
Hemodiálisis domiciliaria
Diálisis peritoneal
Full Text

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a new coronavirus that is affecting the entire global population.1 The clinical presentation varies widely, from asymptomatic to severe respiratory distress requiring mechanical ventilation and admission to an Intensive Care Unit (ICU).2 Severe cases are associated with clotting disorders, thromboembolic complications and a systemic inflammation that can lead to multiple organ dysfunction.3,4

In spite of global measures and lockdowns, on 25 May 2020 the incidence of coronavirus disease 2019 (COVID-19) was still rising, with 5,304,772 laboratory-confirmed cases and more than 342,029 deaths worldwide according to the World Health Organisation. The Spanish Ministry of Health had reported 235,000 confirmed COVID-19 cases in Spain and, according to the Coronavirus Resource Centre of Johns Hopkins University, the incidence in Madrid was 1,021.90 cases per 100,000 inhabitants.

SARS-CoV-2 infection affected more frequently to elderly people with comorbidities, and most studies have focused on populations with chronic obstructive pulmonary disease, hypertension or obesity.5 Patients with chronic kidney disease are a vulnerable population, especially those in end-stage renal disease on dialysis. These patients often have many factors associated with increased risk, such as cardiovascular disease, advanced age, intrinsic frailty and an weakened immune system―.6–8 There is little data on the incidence and course of COVID-19 in dialysis patients. Two recent studies in patients treated with in-centre haemodialysis (HD) found different incidences (2.5% in Wuhan9 and 18.8% in Spain10), but there are no data in the home dialysis population. Home dialysis may imply a protective factor as the repeated contact that occurs with in-centre haemodialysis can be avoided.

The aim of this study is to describe the incidence of COVID-19 in a Home Dialysis Unit (HDU) in Madrid, one of the worst-hit areas in Europe, and to assess its course in this group of patients compared with our in-centre dialysis patients.

Patients and methodsStudy design

This is an observational, retrospective study in all patients of the HDU of Hospital Universitario La Paz (Madrid, Spain) diagnosed with COVID-19 between 10 March and 15 May 2020.

Data collection

Epidemiological, clinical, laboratory and radiological data, as well as the treatments received, were obtained from the hospital's electronic registry data system. The routine blood work included complete blood count, coagulation profile with D-dimer, biochemistry with kidney function, liver function, serum ferritin, lactate dehydrogenase, creatinine kinase, troponin I, C-reactive protein and procalcitonin. We collected the data at the time of the patient's arrival in the Emergency Department and at discharge.

All patients received a chest X-ray and/or chest CT to determine the presence of pneumonia, and all received a nasopharyngeal swab in order to perform a reverse transcription polymerase chain reaction (RT-PCR) test to detect the presence of SARS-CoV-2. A definitive diagnosis of COVID-19 was made based on the following criteria: SARS-CoV-2 positivity by RT-PCR and/or radiographic evidence of pneumonia with typical symptoms (dyspnea, fever or cough) and/or suggestive laboratory results (such as lymphopaenia or D-dimer elevation).

Additionally, we compared the demographic and clinical characteristics of HDU patients with and without COVID-19 infection and of patients on in-centre HD and HDU regimens.

Statistical analysis

Categorical variables are expressed as percentages. Continuous variables are presented as mean and standard deviation if distributed normally, and otherwise as median and range. Variables normally distributed were studied using the Kolmogorov-Smirnov test. Percentages were compared using Fisher's exact test and means with the Mann–Whitney U test (non-parametric data). Statistical analysis was performed with the IBM SPSS Statistics 24 software programme. The study was approved by the Independent Ethics Committee of the Hospital Universitario La Paz.


We analysed a total of 57 peritoneal dialysis (PD) patients and 22 home haemodialysis (HHD) patients treated in our HDU. Twelve (15.1%) were diagnosed with COVID-19: nine (15.7%) were on PD and three (13.6%) were on HHD. The characteristics of patients with and without COVID-19 are shown in Table 1.

Table 1.

Characteristics of home dialysis patients with and without COVID-19 infection.

Variables  Total (n = 79)  COVID-19 (n = 12)  No COVID-19 (n = 67)  p 
Age, years  60 ± 15  62 ± 18.5  60 ± 14.5  0.7 
Male  59 (74.7)  9 (75)  50 (74.6)  0.6 
Type of peritoneal dialysis  57 (72.1)  9 (75)  48 (71.6)  0.9 
CAPD  32 (40.5)  4 (33.3)  28 (41.8)  0.9 
APD  25 (31.6)  5 (41.7)  20 (29.9)  0.9 
Home haemodialysis  22 (27.8)  3 (25)  19 (28.4)  0.9 
Time on dialysis, months  29.8 (0−165)  37.67 (2−107)  28.25 (0−165)  0.8 
Diabetes mellitus  20 (25.3)  4 (33.3)  16 (23.9)  0.4 
CCI  3.7 ± 1.77  3.25 ± 1.48  3.85 ± 1.8  0.8 
CCI age-adjusted  6.54 ± 2.54  6.5 ± 2.5  6.55 ± 2.57  0.9 

Data shown as: total number (percentage), mean and standard deviation or median (range).

APD: automated peritoneal dialysis; CAPD: continuous ambulatory peritoneal dialysis; CCI Charlson comorbidity index.

All patients but one were diagnosed as positive for SARS-CoV-2 using the RT-PCR test; the other patient was diagnosed based on clinical, analytical and radiological data. The mean time from onset of symptoms to RT-PCR diagnosis was 7.2 ± 5.7 days (range 0–18). Eleven patient (91.6%) were hospitalised; the patient who did not require hospitalisation was the only one who did not present pneumonia. Two patients were diagnosed during a hospital admission for other reasons (at 3 and 36 days respectively), (nosocomial transmission, 17%).

The mean age of the patients was 62 ± 18.5 years (range 27–82); 75% were male, all had hypertension and 33.3% had diabetes. Underlying comorbidities are shown in Table 2. With regard to chronic treatments, 10 patients (83.3%) were using renin-angiotensin-aldosterone system inhibitors, two (16.7%) immunosuppressant treatment and three (25%) anticoagulant treatment.

Table 2.

Clinical characteristics of COVID-19 infection.

  Gender; Age (years)  Dialysis  Comorbidities  Chronic treatment  Transmission  Symptoms  PCR+  Radiography  Laboratory criteria  Complications  Admission and length of stay  Oxygen therapy  Treatment  Outcome and duration of illness 
F; 82  CAPD  HTN  RAASi Anticoagulant  Nosocomial  Dyspnoea  Yes  Lobar opacities  Yes  Bacterial superinfection  Yes  Yes  HCQ  Death 
      ACVD    Suspected on day 3 of admission  Diarrhoea        Thromboembolic event  25 days  Reservoir  Antibiotic  22 days 
      Obesity      Skin lesions                 
      CCI: 3;8                       
M; 80  CAPD  DM  RAASi  Nosocomial  Fever  Yes  Bilateral opacities  Yes  No  Yes  Yes    Death 
      SAHS    Suspected on day 17 of admission            37 days  Low flow    2 days 
      CCI: 2;7                       
M; 70  APD  DM  RAASi Anticoagulant  Community  Chest pain  Yes  Bilateral opacities  Yes  Bacterial superinfection  Yes  Yes  HCQ  Cured 
      SAHS                24 days  Ventimask and non-invasive mechanical ventilation  Antibiotic  24 days 
      HTN                    Azithromycin   
      CVD                    Prophylactic anticoagulation   
      CCI: 7;11                       
M; 60  APD  HTN  RAASi  Community  Fever  Yes  Bilateral opacities  Yes  No  Yes  Yes  HCQ  Cured 
      Obesity      Diarrhoea          12 days  Ventimask  Lopinavir  52 days 
      Former smoker                    ritonavir   
      CCI: 2;5                    Azithromycin   
                          Prophylactic anticoagulation   
F; 27  HHD  HTN  RAASi immunosuppressants  Community  Dyspnoea  Yes  Normal  No  No  No  No  HCQ  Cured 
      CVD      Cough                33 days 
      CCI: 2;3      Myalgia                 
M; 71  HHD  DM  No  Community  Fever  Yes  Bilateral opacities  Yes  No  Yes  Yes  HCQ  Cured 
      HTN                8 days  Low flow  corticosteroids  12 days 
      Obesity                    Azithromycin   
      CCI: 4;8                       
M; 29  HHD  HTN  RAASi immunosuppressants  Community  Fever  No  Bilateral opacities  Yes  Bacterial superinfection  Yes  Yes  HCQ  Cured 
      Asthma      Cough          17 days    Tocilizumab  17 days 
      CCI: 2;3      Myalgia              corticosteroids   
M; 73  CAPD  HTN  RAASi Anticoagulant  Community  Low-grade fever  Yes  Bilateral opacities  Yes  Bacterial superinfection  Yes  Yes Ventimask  HCQ  Cured 
      COPD      Diarrhoea          14 days    Antibiotic  18 days 
      Smoker                    Azithromycin   
      Obesity                    Anticoagulant   
      CCI: 4;8                       
M; 64  APD  DM  RAASi  Community  Dyspnoea  Yes  Bilateral opacities  Yes  Bacterial superinfection  Yes  Yes  HCQ  Cured 
      HTN      Fever          12 days  Low flow  Antibiotic  41 days 
      Obesity                    Azithromycin   
      CVD                    Anticoagulant   
      CCI: 4;7                       
10  M; 59  APD  HTN  RAASi  Community  Dyspnoea  Yes  Bilateral opacities  Yes  Bacterial superinfection  Yes  No  HCQ  Cured 
      CVD      Fever          5 days    Antibiotic  30 days 
      CCI: 3;5      Cough              Prophylactic anticoagulation   
11  F; 80  CAPD  HTN  No  Community  Dyspnoea  Yes  Bilateral opacities  Yes  No  Yes  No  HCQ  Cured 
      Obesity      Cough          19 days    Prophylactic anticoagulation  21 days 
      CCI: 4;9      Chest pain                Transferred to HD 
12  M; 51  APD  HTN  RAASi  Community  Fever  Yes  Bilateral opacities  Yes  Bacterial superinfection  Yes  Yes  HCQ  Cured 
      CCI: 2;4      Cough          8 days  Low flow  Antibiotic  19 days 
            Diarrhoea              Azithromycin   

APD: automated peritoneal dialysis; CAPD: continuous ambulatory peritoneal dialysis; CCI: Charlson comorbidity index (normal and age-adjusted); COPD: chronic obstructive pulmonary disease; CVD: cardiovascular disease; DM: diabetes mellitus; Duration of illness: time between positive RT-PCR and recovery or death; F: female; HCQ: hydroxychloroquine; HTN: hypertension; M: Male; RAASi: renin-angiotensin-aldosterone system inhibitors; SAHS: sleep apnoea/hypopnoea syndrome.

Clinical data

Table 2 shows the clinical characteristics of COVID-19 infection. Patients' symptoms started at a mean of 5 ± 4.5 days (range 0–13) before hospital admission. Fever was the most frequent symptom (58%), followed by cough (50%). Two patients attended the Emergency Department due to typical chest pain as the main symptom, one of whom had elevated troponin I but no new lesions on coronary angiography, while the other had neither troponin I elevation nor electrocardiographic alterations.

Ten patients (83%) had bilateral lung opacities in imaging tests, one had only unilateral opacities and one did not have pneumonia. The majority (75%) required oxygen therapy, but only one required non-invasive ventilation. Bacterial superinfection was diagnosed in seven patients (58%). All patients presented lymphopaenia, and 88% had high serum D-dimer levels.

Ten patients (83%) were successfully discharged after a mean of 16.4 ± 9.7 days (range 5–37) of hospitalisation. The mean duration from diagnosis to disease resolution was 25.7 ± 11.4 days (range 12–52). One patient was admitted two days to the ICU.

Two PD patients died during the follow-up period, whereas none of the HHD patients died. The overall mortality rate of patients with COVID-19 was 16.6% (22% on PD, 0% on HHD). Global mortality in our HDU was 2.5% (3.5% for PD, 0% for HHD). The two PD patients who died were diagnosed during a hospital admission due to other causes: one was admitted for haemoperitoneum and the other for a myocardial infarction; both developed multiple organ failure. Table 3 shows the differences between COVID-19 survivors and non-survivors. The patients who died were older and with longer hospital admission. No other differences were found between the two groups. After discharge, one PD patient had to be transferred to in-centre HD as they were unable to continue with self-care following the COVID-19 infection.

Table 3.

Comparison between survivors and non-survivors.

  Survivors (n = 10)  Non-survivors (n = 2) 
Age (years)  58.4 ± 17.98  81 ± 1.41  0.03 
Male  8 (80)  1 (50)  0.46 
Dialysis method
Peritoneal dialysis  7 (70)  2 (100)  0.55 
Home haemodialysis  3 (30)   
Time on dialysis (years)  2.7 ± 2.9  2.5 ± 2.1  0.91 
Charlson comorbidity index
Unadjusted  3.4 ± 1.5  2.5 ± 0.7  0.46 
Age-adjusted  6.3 ± 2.7  7.5 ± 0.7  0.6 
Length of stay  13.22 ± 6  31 ± 8.4  0.03 
Duration of illness (from start of symptoms or suspicion)  26.7 ± 12.3  21 ± 1.4  0.91 
Pneumonia  9 (90)  2 (100)  0.83 
Oxygen therapy  7 (70)  2 (100)  0.55 
Non-invasive ventilation  1 (10)  0.83 
Bacterial superinfection  6 (60)  1 (50)  0.68 
Thromboembolic events  1 (50)  0.18 

Data shown as: total number (percentage) or mean and standard deviation.


This study reports COVID-19 incidence and outcomes in an HDU located in one of the most affected areas in Europe. It is difficult to calculate the worldwide incidence of COVID-19 infection in the general population, but on 25 May 2020 there were 10 cases for every 1000 inhabitants in the Madrid region.11 Our cohort includes 12 patients diagnosed with COVID-19, with an overall incidence of 15.1%: nine were on PD (15.7%) and three on HHD (13.6%). There are no pre-existing data on COVID-19 incidence and outcomes in home dialysis patients. Only one study, from Columbia University Irving Medical Center, described 59 COVID-19 patients, two of whom were being treated with PD.12 Several studies have shown the COVID-19 incidence in HD patients, with differing results. A study in Brescia (Italy) reported 21 patients with COVID-19 out of 400 in-centre HD patients, with an incidence of 5.2%,1 while another Italian study found an incidence of 16%.13 Another report, from Wuhan (China), observed an incidence of 16%,14 while a Spanish study in Madrid shows an incidence of 12.7%.2 In our registry of 199 in-centre HD patients, the incidence has been 16.6% (33 patients) during the same period. Several studies report the potential benefit of home dialysis for COVID-19 prevention, as patients may be safer at home, without the need for regular hospital visits.6,15–18 In our area, however, the incidence was similar between home dialysis and in-centre HD patients. These findings may be linked to the high proportion of the population affected in our geographic area. Moreover, community transmission predominated in our HDU.

The mean age of our patients with COVID-19 was similar to our hospital's cohort,19 but less than that reported in other HD patients.15 The mean age of our in-centre HD cohort with covid was 65.52 ± 17.9 years. The most common symptoms on admission were fever and cough. These manifestations have also been described as the most common in other studies20 and were also the most common in our in-centre haemodialysis cohort. Two patients were treated in the Emergency Department for chest pain, one of whom had high troponin levels. There are studies that report acute cardiac injury in severe cases of COVID-19 infection.21 In a study conducted in Wuhan (China), five of the first 41 patients with COVID-19 presented myocardial injury with troponin elevation, and their main complaint was cardiac symptoms rather than fever or cough.22 In our cohort, most patients (83%) had bilateral opacities in imaging, similar to those described by Goicoechea et al. in in-centre HD patients.2

Two patients died during follow-up, with an overall COVID-19 mortality rate of 16.6% (PD 22%; HHD 0%). In the general population, the estimated mortality varies between 1.4% and 8%.2 One of the largest COVID-19 case series reported in China found an overall mortality rate of 2.3%23; however, in a study conducted in the New York City area, the mortality rate was 21%.24 In Madrid, the overall mortality rate was 21% up to 25 May11 and 20.7% in our hospital cohort,19 which is higher than that observed in our home dialysis patients. Studies of the HD population have shown greater mortality than in the general population. In Brescia, a mortality rate of 29% has been reported.25 Two Spanish studies with in-centre HD patients found different mortality rates. Albalate et al. reported an overall mortality of 16.2%,10 whereas Goicoechea et al. reported 30.5%.2 A study at Columbia University which included two PD patients had a mortality rate of 31%, but the two PD patients survived.12 In our in-centre HD cohort, mortality was 27.3%. Most studies support the fact that COVID-19 mortality is higher in patients with associated conditions/comorbidities.5 In our cohort, the two patients who died were the oldest, as in the Columbia University study.12 Moreover, both were infected via nosocomial transmission, which indicates that their health status was probably worse than the other affected patients.

Comparison of the clinical characteristics and outcome of patients diagnosed with COVID-19 from our HDU and our in-centre HD cohort are summarised in Table 4. COVID-19 from our HDU had lower frequency of pneumonia, less need for oxygen therapy, lower frequency of lymphopaenia (72.7% vs. 100%) and less need for admission in in-centre HD. By contrast, the overall mortality of the 79 patients in our HDU (2.5%), this is lower than the overall morality of the 199 patients in our in-centre HD cohort (4.5%). A reason to explain this difference could be the epidemiological monitoring protocols used in in-centre HD patients, which could favour early diagnosis and admission of the patients at a less advanced stage of the infection. However due to the limited number of patients in the home dialysis group, it is prudent not to draw any conclusions based on these differences.

Table 4.

Comparison between patients diagnosed with COVID-19 on home dialysis and in-centre HD from our hospital.

  HDU (n = 12)  In-centre HD (n = 33) 
Mean age (years)  62 ± 18.5  65.52 ± 17.9 
Male  9 (75)  23 (69.7) 
Positive SARS-CoV-2 RT-PCR  11 (91.6)  29 (87.8) 
Pneumonia  11 (91.6)  23 (69.6) 
Bilateral  10 (83.3)  22 (66.6) 
Oxygen therapy required  9 (75)  22 (66.6) 
Lymphopaenia  12 (100)  22 (66.6) 
Hospital admission  11 (91.6)  28 (84.9) 
Mean stay (days)  16.4 ± 9.7  14.4 ± 11.9 
ICU admission  1 (8.3)  2 (6) 
Mortality  2 (16.6)  9 (27.3) 

Data shown as: total number (percentage) or mean and standard deviation.

To our knowledge, this is the first report describing COVID-19 incidence and outcomes in home dialysis patients. These results come from a region with a high incidence of COVID-19 and may not be representative of other areas. All patients had been discharged from hospital when the results were analysed. Nevertheless, our study has a number of limitations. Firstly, the report does not include asymptomatic patients; only those who attended the Emergency Department and the general incidence may have been higher. Secondly, risk factors for mortality could not be analysed due to the low mortality rate observed. Thirdly, due to its retrospective design, some laboratory tests, such as interleukin-6, were not performed in all patients.

In conclusion, the incidence of COVID-19 infection in our home dialysis unit in Madrid during the peak of the pandemic was high, especially in PD patients. The majority of patients required hospitalisation. Advanced age and nosocomial transmission were the main factors linked to a poor prognosis.

Conflicts of interest

The authors declare that they have no conflicts of interest.


We would like to thank the entire team of doctors, nurses, healthcare assistants, porters, cleaners, administrative staff and other personnel of the Hospital Universitario La Paz for their hard work during the COVID-19 pandemic, and in particular their excellent teamwork. We would also like to thank the haemodialysis centre associated with Hospital La Paz (Centro de Diálisis de Madrid El Pilar [Fresenius Medical Care], Centro de Diálisis Alcobendas [Alcobendas Dialysis Centre] [Fresenius Medical Care] and Centro de Diálisis Diaverum Madrid [Diaverum Madrid Dialysis Centre]) for their important role during the pandemic in lending the logistical support necessary to enable all positive COVID-19 cases to be brought together in the hospital unit and healthy patients diverted to the centres.

F. Alberici, E. Delbarba, C. Manenti, L. Econimo, F. Valerio, A. Pola, et al.
Management of patients on dialysis and with kidney transplantation during the SARS-CoV-2 (COVID-19) pandemic in Brescia, Italy [Internet].
M. Goicoechea, L.A. Sánchez Cámara, N. Macías, A. Muñoz de Morales, ÁG. Rojas, A. Bascuñana, et al.
COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain [Internet].
Kidney International, 98 (2020), pp. 27-34
B. Rowland, V. Kunadian.
Challenges in the management of older patients with acute coronary syndromes in the COVID-19 pandemic.
H.A. Rothan, S.N. Byrareddy.
The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak.
J Autoimmun, 109 (2020), pp. 102433
C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, et al.
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
C. Basile, C. Combe, F. Pizzarelli, A. Covic, A. Davenport, M. Kanbay, et al.
Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres.
Nephrol Dial Transplant [Internet], 35 (2020), pp. 737-741
C. Wu, X. Chen, Y. Cai, J. Xia, X. Zhou, S. Xu, et al.
Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.
A.S. Kliger, M. Cozzolino, V. Jha, G. Harbert, T.A. Ikizler.
Managing the COVID-19 pandemic: international comparisons in dialysis patients.
Kidney Int., 0 (2020),
R. Wang, C. Liao, H. He, C. Hu, Z. Wei, Z. Hong, et al.
COVID-19 in hemodialysis patients: a report of 5 cases.
Am J Kidney Dis, (2020),
M. Albalate, P. Arribas, E. Torres, M. Cintra, R. Alcázar, M. Puerta, et al.
Alta prevalencia de covid19 asintomático en hemodiálisis. Aprendiendo dia a dia el primer mes de pandemia de covid19.
COVID-19. Situación actual en la Comunidad de Madrid. Informe de situación del 24 de mayo. [Accessed 26 May 2020]. Available from: Vol. 438. 2020.
A.M. Valeri, S.Y. Robbins-Juarez, J.S. Stevens, W. Ahn, M.K. Rao, J. Radhakrishnan, et al.
Presentation and Outcomes of Patients with ESKD and COVID-19.
J Am Soc Nephrol [Internet], (2020),
R. Scarpioni, A. Manini, T. Valsania, S. De Amicis, V. Albertazzi, L. Melfa, et al.
Covid-19 and its impact on nephropathic patients: the experience at Ospedale “Guglielmo da Saliceto” in Piacenza [Internet]. Vol. 37, Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia.
Y. Ma, B. Diao, X. Lv, J. Zhu, W. Liang, L. Liu, et al.
2019 novel coronavirus disease in hemodialysis (HD) patients: report from one HD center in Wuhan, China.
medRxiv, (2020),
M. Wilkie, S. Davies.
Peritoneal dialysis in the time of COVID-19.
Perit Dial Int J Int Soc Perit Dial [Internet], (2020),
T.W. Meyer, T.H. Hostetter, S. Watnick.
Twice-weekly hemodialysis is an option for many patients in times of dialysis unit stress.
J Am Soc Nephrol, 31 (2020),
O. El Shamy, S. Sharma, J. Winston, J. Uribarri.
Peritoneal dialysis during the coronavirus disease-2019 (COVID-19) pandemic: acute inpatient and maintenance outpatient experiences.
Kidney Med, (2020),
X.-L. Lai, H.-Y. Wang, Z.-Y. Guo.
Recommendations for prevention and management of COVID-19 in peritoneal dialysis patients.
Chronic Dis Transl Med, (2020),
A.M. Borobia, A.J. Carcas, F. Arnalich, R. Alvarez-Sala, J. Montserrat, M. Quintana, et al.
A cohort of patients with COVID-19 in a major teaching hospital in Europe.
J Clin Med, 9 (2020), pp. 1733
A.J. Rodriguez-Morales, J.A. Cardona-Ospina, E. Gutiérrez-Ocampo, R. Villamizar-Peña, Y. Holguin-Rivera, J.P. Escalera-Antezana, et al.
Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis.
Travel Med Infect Dis, 34 (2020), pp. 101623
M. Madjid, P. Safavi-Naeini, S.D. Solomon, O. Vardeny.
Potential effects of coronaviruses on the cardiovascular system: a review.
JAMA Cardiology, (2020),
Y.Y. Zheng, Y.T. Ma, J.Y. Zhang, X. Xie.
COVID-19 and the cardiovascular system. Vol. 17, Nature Reviews Cardiology. Nature Research.
(2020), pp. 259-260
Z. Wu, J.M. McGoogan.
Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention.
JAMA, 323 (2020), pp. 1239-1242
S. Richardson, J.S. Hirsch, M. Narasimhan, J.M. Crawford, T. McGinn, K.W. Davidson, et al.
Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area.
F. Alberici, E. Delbarba, C. Manenti, L. Econimo, F. Valerio, A. Pola, et al.
A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection.
Kidney Int [Internet], 0 (2020),

Please cite this article as: Maldonado M, Ossorio M, del Peso G, Santos-Alonso C, Álvarez L, Sánchez-Villanueva R, et al. Incidencia y resultados de la COVID-19 en una unidad de diálisis domiciliaria en Madrid (España) durante el pico de la pandemia. Nefrologia. 2020.

Copyright © 2020. Sociedad Española de Nefrología
Nefrología (English Edition)

Subscribe to our newsletter

Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?